Sign in Subscribe
Vaccines

AstraZeneca Pauses £200 Million Investment in Cambridge Research Site Amid Industry Frustrations

Strategic Insights

— 2 min read

AstraZeneca, Britain's most valuable public company, has put on hold a planned £200 million investment in its Cambridge research site, a move that raises further concerns about the UK's life sciences strategy. This decision comes on the heels of AstraZeneca's earlier scrapping of a £450 million expansion of its vaccine manufacturing plant in Liverpool. The company blamed the UK government for missing an internal deadline and changing the level of support it was offering. This development is the latest blow to the government's life sciences strategy, which has identified the sector as one of the key growth areas.

Key Takeaways:

  • AstraZeneca has paused a planned £200 million investment in its Cambridge research site, which was set to create 1,000 jobs.
  • The decision follows the company's earlier scrapping of a £450 million expansion of its vaccine manufacturing plant in Liverpool.
  • AstraZeneca blamed the UK government for missing an internal deadline and changing the level of support it was offering.
  • The company has declined to comment on its London listing, with chief executive Sir Pascal Soriot privately discussing the possibility of moving the company's listing to the United States, as reported by The Times in July.
  • Merck, a US drugs giant, has also scrapped a £1 billion investment in a research centre in London, which had been expected to be completed by 2027.
  • Industry leaders have warned that other multinational drugs companies could withhold investment in the UK.
  • Richard Torbett, the chief executive of the Association of the British Pharmaceutical Industry, has stated that Merck's decision "could be the canary in the coal mine ... we know other companies are taking a hard look at their UK investments".

Statistics:

  • AstraZeneca's planned investment in Cambridge was valued at £200 million.
  • The planned investment was expected to create 1,000 jobs.
  • AstraZeneca has scrapped a £450 million expansion of its vaccine manufacturing plant in Liverpool.
  • Merck's scrapped investment in London was valued at £1 billion.
  • The site was expected to be completed by 2027.
  • The government has committed up to £600 million to the health data research service and up to £520 million to the life sciences innovative manufacturing fund.
  • The NHS sales scheme and limitations on the reimbursement of new medicines have been cited as contributing factors to the industry's frustrations.

Sources:

  • "AstraZeneca pausing £200m investment in Cambridge research site amid industry frustrations" (The Times, 27 August 2023)
  • "Merck scraps £1bn research centre investment in London" (The Times, 23 August 2023)
  • "Labour government's life sciences strategy under threat as AstraZeneca pauses investment" (The Times, 27 August 2023)
  • "Association of the British Pharmaceutical Industry" (www.abpi.org.uk)
  • "UK government's industrial strategy" (www.gov.uk/government/publications/industrial-strategy-white-paper)
  • "AstraZeneca's plans to invest up to $50 billion in America by the end of the decade" (AstraZeneca press release, 2023)
  • "Merck's planned investment in London" (Merck press release, 2023)

Read more